拳头产品国内销售大增52%,亚盛医药去年亏损收窄,欲挑战艾伯维血液肿瘤明星药

时代财经
28 Mar

营收的大幅增长主要得益于武田制药的知识产权收入及药品销售增加。得益于武田制药的知识产权收入及药品销售增加,创新药企亚盛医药(06855.HK;AAPG.O)2024年实现营收大幅增长。根据3月27日晚公布的2024年全年业绩,2024年,公司实现收入9.81亿元,较上年同比增长342%;亏损额由上年的9.23亿元同比下降56.2%至4.06亿元。其中,亚盛医药核心产品奥雷巴替尼(商品名:耐立克)在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10